

Hematologies, Inc.

3161 Elliott Ave Suite 200
Seattle, WA 98121
(206) 223-2700 or (800) 860-0934
Fax (206) 223-5550
www.hematologies.com

HLID#: PATIENT NAME: .
PATIENT ID#: DOB : SEX:
NPI: ORDERING PHYSICIAN:
SPECIMEN TYPE: Bone Marrow Aspirate
COLLECTION DATE: RECEIPT DATE:
REPORT DATE: ICD-9: UNITS: 1 Microarray
CLINIC ID#: ACCOUNT: CPT:

Patient Name HLID#

Specimen Type: Bone Marrow Aspirate

Clinical History/Indications: A xx year old male with a listed clinical history of myelodysplastic syndrome (MDS). Previous flow cytometry results revealed abnormal myeloid antigen expression and abnormal myeloblasts in 1.2% of the bone marrow, **FISH and cytogenetic studies were negative** (see separate reports).

aCGH/SNP Microarray : ABNORMAL

Positive for gain of 8q24.13-q24.21 (4 Mb) [including c-MYC]

Interpretation:

- **These findings reveal the presence of an aberrant cell population harboring a 4 Mb gain at 8q24.**
- **Amplification of the c-MYC gene (located at 8q24) has been reported in MDS and AML [Storlazzi et al. 2006 Hum Mole Gene 15/6].**
- **Clinical and histological correlation required for definitive diagnosis.**

The presence of chromosome aberrations and LOH/UPD** below the detection sensitivity of this analysis (20% for gains and losses; 1 Mb in length for gains or losses and 20 Mb for LOH/UPD) cannot be completely ruled out.*

***Loss of heterozygosity (LOH)** is defined as consecutive homozygous SNP tracts exceeding 1Mb in length. LOH can result from deletion of all copies of one homolog or from **uniparental disomy** (UPD)** in which both copies, or region, of a chromosome pair have the same parental origin. Regions of UPD are continuous stretches of homozygous SNP calls (LOH) *without copy number loss*. Both LOH and UPD play known roles in tumorigenesis.


Method: Genomic DNA was isolated from the whole bone marrow aspirate. Oligonucleotide array-based comparative genomic hybridization (array CGH) and SNP (single nucleotide polymorphism) analysis of 180,000 genomic loci, including ~20,000 cancer-associated CGH as well as ~60,000 SNP probes, was performed on the extracted DNA sample and referenced to a normal male DNA sample.

HLID#: PATIENT NAME:
UNITS: 1
SPECIMEN TYPE: Bone Marrow Aspirate

COLLECTION DATE:

DOB :

SEX:
CLINIC ID#:



Electronically signed by: Barbara K. Zehentner, Ph.D., HCLD (ABB), Director of Molecular Analysis and Denise A. Wells, MD, Medical Director
This test was developed and its performance characteristics determined by **HematoLogics, Inc.** It has not been cleared or approved by the US Food and Drug Administration